Search Within

Alison Moskowitz

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (56)
  2. Journal Article (33)
  3. Research Letter (6)
  4. Review (1)
Groups
  1. Center for Hematologic Malignancies (96)
  2. Department of Medicine (96)
  3. Hematologic Malignancies, Division of (96)
  4. Lymphoma (96)
  5. Sloan Kettering Institute Postdocs (96)
  6. Population Sciences Research Program (90)

More Groups

People
  1. Steven Horwitz (90)
  2. Ariela Noy (60)
  3. Andrew Zelenetz (58)
  4. Anita Kumar (58)
  5. Paul Hamlin (56)
  6. Maria Palomba (55)

More People

Years
  1. 2025 (5)
  2. 2024 (6)
  3. 2023 (14)
  4. 2022 (5)
  5. 2021 (12)
  6. 2020 (18)

More Years

Publications
  1. Blood (41)
  2. Hematological Oncology (8)
  3. Blood Advances (6)
  4. Blood Cancer Journal (6)
  5. Journal of Clinical Oncology (6)
  6. Haematologica (4)

More Publications

Publishers
  1. American Society of Hematology (47)
  2. Wiley Blackwell (13)
  3. American Society of Clinical Oncology (6)
  4. Nature Publishing Group (6)
  5. Elsevier Inc. (5)
  6. Ferrata Storti Foundation (4)

More Publishers

Results (96)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era treated at Memorial Sloan Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P.; Horwitz, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2017)

    Fulltext@MSK | Save
  • Utility of imaging in cutaneous marginal zone lymphoma
    Meeting Abstract

    Geller, S.; Dai, J.; Myskowski, P.; Kim, Y. H.; Moskowitz, A.; Pulitzer, M.; Hoppe, R.; Horwitz, S. M.; Kheterpal, M.
    Journal of Investigative Dermatology (2017)

    Fulltext@MSK | Save
  • Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save